{
    "clinical_study": {
        "@rank": "122764", 
        "arm_group": {
            "arm_group_label": "high dose ATG,low dose ATG", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Severe acquired aplastic anaemia (SAA) is a life-threatening disease characterized by\n      pancytopenia and hypoplastic bone marrow. Immunosuppressive treatment with antithymocyte\n      globulin (ATG)and cyclosporine remain the standard regimen with response rates of 70% or\n      more and excellent overall survival. However ,there are no clinical trials to illustrate the\n      response and complete remission rate  with different doses of ATG.And there are no data\n      reported on children with SAA so far."
        }, 
        "brief_title": "Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Aplastic Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Aplastic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  clinical  diagnosis of childhood acquired severe aplastic anemia(SAA)\n\n        Exclusion Criteria:\n\n          -  clinical  diagnosis of no childhood acquired severe aplastic anemia(SAA)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01997372", 
            "org_study_id": "Xzhu"
        }, 
        "intervention": {
            "arm_group_label": "high dose ATG,low dose ATG", 
            "description": "Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d  ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug  prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) \uff1e1\u00d7109/L.", 
            "intervention_name": "ATG", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ATG", 
            "SAA", 
            "immunosuppressive treatment", 
            "cyclosporine"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "contact": {
                "email": "zhuxiaof@yahoo.com.cn", 
                "last_name": "Xiaofan Zhu, MD", 
                "phone": "+86 22 23909001"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300020"
                }, 
                "name": "Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Different Doses of Anti-thymocyte Globin With 2.5 or 3.75mg/kg to Treat Child Severe Aplastic Anemia", 
        "overall_contact": {
            "email": "zhuxiaof@yahoo.com.cn", 
            "last_name": "Xiaofan Zhu, MD", 
            "phone": "+86 22 23909001"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Complete response (CR) was defined as achieving normal levels of hemoglobin adjusted for age, platelet count >100\u00d7109/L, and ANC>1.5\u00d7109/L. Partial response (PR) was defined as transfusion independence, reticulocyte count >30\u00d7109/L, platelet count >20\u00d7109/L, and ANC >0.5\u00d7109/L above the baseline. Persistence of transfusion requirement or death was evidence of no response (NR).", 
            "measure": "the response and complete remission rate with different doses of ATG to treat child severe aplastic anemia", 
            "safety_issue": "No", 
            "time_frame": "1 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01997372"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Xiaofan Zhu", 
            "investigator_title": "Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "1090310", 
            "citation": "Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975 Mar;45(3):355-63."
        }, 
        "secondary_outcome": {
            "description": "relapse was defined as  transfusion dependence again; or progressed to paroxysmal nocturnal hemoglobinuria (PNH) /acute myeloid leukemia/myelodysplasia syndrome (MDS); or CSA dependence", 
            "measure": "the relapse rate with different doses of ATG to treat child severe aplastic anemia", 
            "safety_issue": "No", 
            "time_frame": "4-10 years"
        }, 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}